Advanced Infusion Care (AIC) Now Provides Glassia® and Aralast® NP by Takeda
AIC, a division of AIS Healthcare, has enriched its portfolio of infusion therapies by offering GLASSIA and ARALAST NP,...
JCR Pharmaceuticals Achieves Milestone with J-Brain Cargo® in Neurodegenerative Disease Research Collaboration with Alexion
JCR Pharmaceuticals Co., Ltd. (JCR), a leading specialty pharmaceutical company, has announced the achievement of a significant research milestone...
Takeda’s Iclusig® Granted FDA Approval for Newly Diagnosed Ph+ ALL
Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved ICLUSIG® (ponatinib) for the treatment of...
GRAIL Unveils Innovative Risk Classification Test for Lung Cancer Study
GRAIL, LLC, a pioneering healthcare company dedicated to early cancer detection for potential curative treatment, has partnered with AstraZeneca...
BMS Strengthens Neuroscience Portfolio with Karuna Therapeutics Acquisition
Bristol Myers Squibb (BMS) has announced the completion of its acquisition of Karuna Therapeutics, Inc., marking a significant expansion...
Immunis Chairman Dr. Hans Keirstead Presents Abundance360 Moonshot
Immunis, Inc., an innovative biotech firm, announced that its Chairman, Dr. Hans Keirstead, will present at the prestigious Abundance360...
FDA Approves Breyanzi® as First CAR-T Therapy for CLL/SLL
Bristol Myers Squibb announced the accelerated FDA approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR)...
Pfizer’s Phase 3 Trial Shows Positive Survival in DLBCL
Pfizer Inc. has announced promising Phase 3 study results for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab...
Merck Successfully Acquires Harpoon Therapeutics, Inc.
Merck has successfully completed the acquisition of Harpoon Therapeutics, Inc., making Harpoon a wholly-owned subsidiary of Merck. As a...
Viiv Healthcare Presents Promising Cabenuva Data at CROI
ViiV Healthcare has announced promising interim data from the LATITUDE phase III trial, presented at the CROI 2024. The...